Physician profile
David A Parks
NPI 1649315219
$50,391.71
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $6,985 · 2021: $1,521.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $37,803.57 | 2019-2021 | |
| Viiv Healthcare Company | $11,214.91 | 2019-2021 | |
| Theratechnologies INC. | $843.23 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $204.16 | 2019-2021 | |
| Janssen Products, LP | $99.95 | 2019 | |
| Emd Serono, INC. | $89.42 | 2019-2021 | |
| Janssen Biotech, INC. | $49.52 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.54 | 2020 | |
| Amgen INC. | $23.26 | 2019-2020 | |
| Vyera Pharmaceuticals, LLC | $16.35 | 2019 | |
| Abbvie INC. | $14.54 | 2020 | |
| Janssen Pharmaceuticals, INC | $5.26 | 2019 |
Research and ownership
$877.88 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Parks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.